The Effects of Sirolimus and Magnesium on Primary Human Coronary Endothelial Cells: An In Vitro Study

Drug eluting magnesium (Mg) bioresorbable scaffolds represent a novel paradigm in percutaneous coronary intervention because Mg-based alloys are biocompatible, have adequate mechanical properties and can be resorbed without adverse events. Importantly, Mg is fundamental in many biological processes, mitigates the inflammatory response and is beneficial for the endothelium. Sirolimus is widely used as an antiproliferative agent in drug eluting stents to inhibit the proliferation of smooth muscle cells, thus reducing the occurrence of stent restenosis. Little is known about the potential interplay between sirolimus and Mg in cultured human coronary artery endothelial cells (hCAEC). Therefore, the cells were treated with sirolimus in the presence of different concentrations of extracellular Mg. Cell viability, migration, barrier function, adhesivity and nitric oxide synthesis were assessed. Sirolimus impairs the viability of subconfluent, but not of confluent cells independently from the concentration of Mg in the culture medium. In confluent cells, sirolimus inhibits migration, while it cooperates with Mg in exerting an anti-inflammatory action that might have a role in preventing restenosis and thrombosis.

[1]  G. Fedele,et al.  Magnesium and the Brain: A Focus on Neuroinflammation and Neurodegeneration , 2022, International journal of molecular sciences.

[2]  Jingen Li,et al.  Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction: A systematic review and meta-analysis of randomized clinical trials , 2022, Frontiers in Cardiovascular Medicine.

[3]  M. Joner,et al.  Challenges of the newer generation of Resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation. , 2022, Journal of cardiology.

[4]  Kuai-she Wang,et al.  A review on magnesium alloys for biomedical applications , 2022, Frontiers in Bioengineering and Biotechnology.

[5]  E. Weitzberg,et al.  Nitric oxide signaling in health and disease , 2022, Cell.

[6]  S. Simon,et al.  mTOR contributes to endothelium-dependent vasorelaxation by promoting eNOS expression and preventing eNOS uncoupling , 2022, Communications Biology.

[7]  Yu-xiao Liu,et al.  Advances in the development of biodegradable coronary stents: A translational perspective , 2022, Materials today. Bio.

[8]  Ying He,et al.  In Vitro Study of Endothelial Cell Morphology and Gene Expression in Response to Wall Shear Stress Induced by Arterial Stenosis , 2022, Frontiers in Bioengineering and Biotechnology.

[9]  Sung‐Jin Hong,et al.  Drug-eluting stents for the treatment of coronary artery disease: A review of recent advances , 2022, Expert opinion on drug delivery.

[10]  Jiping Lu,et al.  Structural Design of Vascular Stents: A Review , 2021, Micromachines.

[11]  S. Castiglioni,et al.  High Magnesium and Sirolimus on Rabbit Vascular Cells—An In Vitro Proof of Concept , 2021, Materials.

[12]  T. Villarreal-Molina,et al.  Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches , 2021, International journal of molecular sciences.

[13]  S. Castiglioni,et al.  Magnesium Deficiency Induces Lipid Accumulation in Vascular Endothelial Cells via Oxidative Stress—The Potential Contribution of EDF-1 and PPARγ , 2021, International journal of molecular sciences.

[14]  U. Ralapanawa,et al.  Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review , 2021, Journal of epidemiology and global health.

[15]  S. Castiglioni,et al.  Magnesium and inflammation: Advances and perspectives. , 2020, Seminars in cell & developmental biology.

[16]  B. Yan,et al.  BIOSOLVE‐IV‐registry: Safety and performance of the Magmaris scaffold: 12‐month outcomes of the first cohort of 1,075 patients , 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  M. Joner,et al.  Preclinical investigation of neoatherosclerosis in magnesium-based bioresorbable scaffolds versus thick-strut drug-eluting stents. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  A. Malik,et al.  Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation , 2020, eLife.

[19]  B. Kwak,et al.  Endothelial connexins in vascular function , 2019, Vascular biology.

[20]  R. Franke,et al.  Vascular Endothelial Cell Biology: An Update , 2019, International journal of molecular sciences.

[21]  R. Steward,et al.  Probing Endothelial Cell Mechanics through Connexin 43 Disruption , 2018, Experimental Mechanics.

[22]  S. Hassanajili,et al.  Cardiovascular stents: overview, evolution, and next generation , 2018, Progress in Biomaterials.

[23]  S. Castiglioni,et al.  The Contribution of EDF1 to PPARγ Transcriptional Activation in VEGF-Treated Human Endothelial Cells , 2018, International journal of molecular sciences.

[24]  Liguo Zhao,et al.  Research into biodegradable polymeric stents: a review of experimental and modelling work , 2018, Vessel Plus.

[25]  Mary E. Haas,et al.  Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling , 2018, Circulation.

[26]  D. Sedding,et al.  Systemic application of sirolimus prevents neointima formation not via a direct anti-proliferative effect but via its anti-inflammatory properties. , 2017, International journal of cardiology.

[27]  A. Malik,et al.  Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability. , 2017, Circulation research.

[28]  Yong-jun Cao,et al.  Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-κB/LOX-1 Pathway , 2016, PloS one.

[29]  A. Orekhov,et al.  Endothelial Barrier and Its Abnormalities in Cardiovascular Disease , 2015, Front. Physiol..

[30]  D. Vestweber,et al.  How leukocytes cross the vascular endothelium , 2015, Nature Reviews Immunology.

[31]  Yingzi Zhao,et al.  Vascular nitric oxide: Beyond eNOS. , 2015, Journal of pharmacological sciences.

[32]  Peter J. Murphy,et al.  Surface treatments for controlling corrosion rate of biodegradable Mg and Mg-based alloy implants , 2015, Science and technology of advanced materials.

[33]  S. Castiglioni,et al.  Magnesium alloys for vascular stents: the biological bases , 2015 .

[34]  M. Schwartz,et al.  ZO-1 controls endothelial adherens junctions, cell–cell tension, angiogenesis, and barrier formation , 2015, The Journal of cell biology.

[35]  A. Finn,et al.  Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C-&agr; Activation and Disruption of the p120–Vascular Endothelial Cadherin Interaction , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[36]  E. Dejana,et al.  VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. , 2013, Developmental cell.

[37]  J. Maier Endothelial cells and magnesium: implications in atherosclerosis. , 2012, Clinical science.

[38]  Patrick W Serruys,et al.  Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization? , 2011, Circulation.

[39]  S. Marx,et al.  Rapamycin Regulates Endothelial Cell Migration through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1* , 2010, The Journal of Biological Chemistry.

[40]  F. Orsenigo,et al.  The role of adherens junctions and VE-cadherin in the control of vascular permeability , 2008, Journal of Cell Science.

[41]  D. Vestweber,et al.  VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[42]  D. Vestweber Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium , 2007, Immunological reviews.

[43]  R. Virmani,et al.  Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents , 2005, Circulation.

[44]  A. Mazur,et al.  Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. , 2004, Biochimica et biophysica acta.

[45]  D. Wagner,et al.  Leukocyte-endothelium adhesion molecules in atherosclerosis. , 1998, The Journal of laboratory and clinical medicine.

[46]  J. Badimón,et al.  Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.

[47]  H. Garcia-Garcia,et al.  Second-generation drug-eluting resorbable magnesium scaffold: Review of the clinical evidence. , 2019, Cardiovascular revascularization medicine : including molecular interventions.

[48]  R. de Caterina,et al.  Endothelial permeability, LDL deposition, and cardiovascular risk factors—a review , 2018, Cardiovascular research.

[49]  G. Homuth,et al.  Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro. , 2012, Journal of biomedical materials research. Part B, Applied biomaterials.